CHC MontLegia

At CHC MontLegia the cardiology team investigates ways to lower the burden of heart‑related events, focusing on stroke prevention, acute coronary care, and rhythm disorders. Trials aim to test new anticoagulant agents and refine treatment pathways for patients after a non‑cardioembolic ischemic stroke or high‑risk transient ischemic attack, as well as for those with non‑ST‑segment elevation acute coronary syndrome and atrial fibrillation.

• Reducing recurrent ischemic stroke risk
• Optimizing antiplatelet therapy in acute coronary syndrome
• Comparing novel FXIa inhibitor with standard anticoagulants
• Evaluating bleeding safety profiles in cardiac patients

The research integrates real‑world patient monitoring and leverages a network of 36 investigators to generate evidence that could reshape preventive cardiology across Europe.

The department conducts studies on inflammatory bowel conditions, aiming to improve long‑term remission and quality of life. Trials compare biologic agents for patients with moderate to severe Crohn's disease or ulcerative colitis who have failed previous therapies.

• Head‑to‑head comparison of risankizumab and ustekinumab
• Long‑term safety monitoring of biologic treatment
• Pediatric pharmacokinetics and efficacy in young Crohn's patients
• Assessment of endoscopic improvement as a therapeutic endpoint

By enrolling both adult and pediatric cohorts, the site seeks to generate data that support personalized therapeutic strategies for chronic digestive disorders.

Research at the facility includes oncology trials targeting women’s reproductive health, specifically exploring adjuvant immunotherapy for high‑risk endometrial cancer following curative surgery.

• Evaluation of pembrolizumab combined with chemotherapy
• Measurement of disease‑free and overall survival
• Radiographic and histopathologic assessment of recurrence
• Safety profiling in post‑surgical patients

The study aims to determine whether adding immunotherapy can enhance long‑term outcomes for women undergoing standard cancer treatment.

Immunology‑focused investigations evaluate novel vaccines and antiviral strategies for vulnerable populations, such as immunocompromised children at risk for herpes zoster.

• Reactogenicity and safety of a pediatric subunit herpes zoster vaccine
• Humoral immune response measurement post‑vaccination
• Assessment in renal transplant recipients aged 1‑17 years
• Monitoring of adverse events through two‑month follow‑up

Findings will inform vaccination guidelines for young patients with compromised immunity across the European region.

Oncology trials at CHC MontLegia span several tumor types, from lung and pancreatic cancers to lymphoma and triple‑negative breast cancer, with a central goal of improving survival through innovative therapeutic combinations.

• Adjuvant pembrolizumab in high‑risk endometrial cancer
• Pre‑operative chemo‑radiotherapy for resectable non‑small cell lung cancer
• Autologous stem cell transplantation for peripheral T‑cell lymphoma
• Sacituzumab govitecan efficacy in metastatic triple‑negative breast cancer
• Vinblastine monotherapy in ALK‑positive anaplastic large cell lymphoma
• Stereotactic body radiation combined with chemotherapy for borderline resectable pancreatic adenocarcinoma

The multidisciplinary approach integrates surgical, medical, and radiation expertise to generate evidence that may change standard of care for these aggressive cancers.

Neurological research concentrates on acute cerebrovascular events, evaluating novel agents that could limit brain injury and improve functional recovery after spontaneous intracerebral haemorrhage or ischemic stroke.

• Safety and tolerability of Ir‑CPI in intracerebral haemorrhage patients
• Assessment of bleeding risk with novel anticoagulants post‑stroke
• Functional outcome measures in acute stroke cohorts
• Biomarker analysis for hemorrhagic versus ischemic injury

By focusing on early intervention, the trials seek to reduce long‑term disability and enhance recovery pathways for stroke survivors.

The site evaluates cutting‑edge diagnostic tools and therapeutic devices that support precision medicine across its diverse trial portfolio.

• Radiographic assessment of disease‑free survival in oncology studies
• Central blinded review of event‑free survival endpoints
• Advanced imaging for R0 resection margin determination
• Real‑time monitoring of coagulation parameters during antithrombotic therapy

These technologies enable consistent endpoint evaluation and improve the reliability of trial outcomes for investigators and regulatory bodies.

Studies explore the underlying physiological processes that drive gastrointestinal inflammation, aiming to identify biomarkers that predict response to biologic treatment.

• Correlation of mucosal cytokine levels with endoscopic remission
• Evaluation of gut microbiome shifts during therapy
• Oral health assessments as indicators of systemic inflammation
• Longitudinal tracking of digestive motility patterns

Insights from these investigations could refine patient selection and personalize management strategies for chronic digestive disorders.

Immunological trials assess how novel agents modulate immune pathways, with a focus on safety and efficacy in both cancer and infectious disease settings.

• Evaluation of ABX464 for clinical remission in ulcerative colitis
• Immune response profiling after herpes zoster vaccination
• Impact of FXIa inhibition on thrombo‑inflammatory cascades
• Mechanistic studies of checkpoint inhibitors in lung cancer

The research contributes to a deeper understanding of immune regulation, supporting the development of therapies that balance efficacy with manageable safety profiles.